MX360304B - Composiciones de activador de glucocinasa para el tratamiento de la diabetes. - Google Patents
Composiciones de activador de glucocinasa para el tratamiento de la diabetes.Info
- Publication number
- MX360304B MX360304B MX2014013105A MX2014013105A MX360304B MX 360304 B MX360304 B MX 360304B MX 2014013105 A MX2014013105 A MX 2014013105A MX 2014013105 A MX2014013105 A MX 2014013105A MX 360304 B MX360304 B MX 360304B
- Authority
- MX
- Mexico
- Prior art keywords
- diabetes
- treatment
- glucokinase activator
- cyclohexyl
- activator compositions
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 229940124828 glucokinase activator Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- HPGJSAAUJGAMLV-UHFFFAOYSA-N 2-[[2-[[cyclohexyl-(4-propoxycyclohexyl)carbamoyl]amino]-1,3-thiazol-5-yl]sulfanyl]acetic acid Chemical compound C1CC(OCCC)CCC1N(C(=O)NC=1SC(SCC(O)=O)=CN=1)C1CCCCC1 HPGJSAAUJGAMLV-UHFFFAOYSA-N 0.000 abstract 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 abstract 1
- 108010011459 Exenatide Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 229940127003 anti-diabetic drug Drugs 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 229960001519 exenatide Drugs 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 abstract 1
- 229960004034 sitagliptin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648110P | 2012-05-17 | 2012-05-17 | |
| PCT/US2013/041076 WO2013173417A2 (en) | 2012-05-17 | 2013-05-15 | Glucokinase activator compositions for the treatment of diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014013105A MX2014013105A (es) | 2015-04-08 |
| MX360304B true MX360304B (es) | 2018-10-29 |
Family
ID=48576527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013105A MX360304B (es) | 2012-05-17 | 2013-05-15 | Composiciones de activador de glucocinasa para el tratamiento de la diabetes. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10004782B2 (enExample) |
| EP (1) | EP2849776B1 (enExample) |
| JP (1) | JP6234443B2 (enExample) |
| KR (2) | KR20150013838A (enExample) |
| CN (2) | CN118453592A (enExample) |
| AU (2) | AU2013262895A1 (enExample) |
| BR (1) | BR112014028622A2 (enExample) |
| CA (1) | CA2872021C (enExample) |
| EA (1) | EA201492109A1 (enExample) |
| ES (1) | ES2878001T3 (enExample) |
| HK (1) | HK1202458A1 (enExample) |
| IL (1) | IL235484A0 (enExample) |
| IN (1) | IN2014DN09554A (enExample) |
| MX (1) | MX360304B (enExample) |
| SG (2) | SG10201609644UA (enExample) |
| WO (1) | WO2013173417A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2576524T (pt) | 2010-05-26 | 2017-11-17 | Vtv Therapeutics Llc | Resumo |
| IN2014DN09554A (enExample) * | 2012-05-17 | 2015-07-17 | Transtech Pharma Llc | |
| KR102408480B1 (ko) | 2018-05-30 | 2022-06-10 | 이삼구 | 당뇨질환의 치료용 조성물 |
| BR112020024269A2 (pt) * | 2018-05-31 | 2021-02-23 | Hua Medicine (Shanghai) Ltd. | combinação farmacêutica, composição e formulação de combinação contendo ativador de glucoquinase e ativador de receptor ppar e métodos de preparação e usos dos mesmos |
| CA3093025A1 (en) | 2018-06-12 | 2019-12-19 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| AU2020426356A1 (en) * | 2020-01-31 | 2022-08-25 | Hua Medicine (Shanghai) Ltd. | Treating treatment-resistant diabetes with glucokinase activator |
| US11872221B2 (en) | 2020-01-31 | 2024-01-16 | Hua Medicine (Shanghai) Ltd. | Treating untreated or treatment-resistant diabetes with glucokinase activator |
| US12391658B2 (en) | 2020-02-18 | 2025-08-19 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| WO2021243646A1 (en) * | 2020-06-04 | 2021-12-09 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with hepatic impairment |
| CA3185831A1 (en) * | 2020-06-04 | 2021-12-09 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
| US11857536B2 (en) | 2020-06-04 | 2024-01-02 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
| US12479808B2 (en) | 2020-06-08 | 2025-11-25 | Vtv Therapeutics Llc | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
| CA3181665A1 (en) * | 2020-06-08 | 2021-12-16 | Jing TENG | Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof |
| CN115350268B (zh) * | 2022-08-24 | 2025-02-11 | 深圳青澜生物技术有限公司 | 一种用于治疗糖尿病的制剂、微针及其制备工艺 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT323195B (de) | 1973-03-16 | 1975-06-25 | Hurka Wilhelm | Verfahren zur herstellung neuer salze von biguaniden |
| FR2243684B1 (enExample) | 1973-09-19 | 1977-01-28 | Semb | |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| US6794412B1 (en) * | 1999-03-11 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin |
| SI1133312T1 (sl) * | 1999-06-21 | 2008-02-29 | Lilly Co Eli | Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina |
| US6294546B1 (en) * | 1999-08-30 | 2001-09-25 | The Broad Of Trustees Of The Leland Stanford Junior University | Uses of diterpenoid triepoxides as an anti-proliferative agent |
| US6608038B2 (en) * | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
| CA2744893A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as glucokinase activators |
| WO2004076420A1 (ja) | 2003-02-26 | 2004-09-10 | Banyu Pharmaceutical Co., Ltd. | ヘテロアリールカルバモイルベンゼン誘導体 |
| JP4386035B2 (ja) | 2003-07-14 | 2009-12-16 | ソニー株式会社 | 情報提供システム、放送局特定サーバ、関連情報提供サーバ、コンテンツ配信サーバ、記録媒体販売サーバ及び情報提供方法 |
| WO2005023766A1 (en) | 2003-09-11 | 2005-03-17 | Biocon Limited | Salt of atorvastatin with metformin |
| CN1910166B (zh) * | 2004-01-06 | 2012-01-04 | 诺和诺德公司 | 杂芳基脲及其作为葡糖激酶活化剂的用途 |
| BRPI0506662B8 (pt) * | 2004-01-06 | 2021-05-25 | Novo Nordisk As | compostos ativadores de glucoquinase |
| EP1758611A2 (en) * | 2004-06-17 | 2007-03-07 | Novo Nordisk A/S | Use of liver-selective glucokinase activators |
| WO2006110809A2 (en) | 2005-04-12 | 2006-10-19 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
| US20100028439A1 (en) | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
| CN101258137A (zh) * | 2005-07-08 | 2008-09-03 | 诺沃-诺迪斯克有限公司 | 双环烷基脲葡糖激酶活化剂 |
| JP2009500378A (ja) | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー／エス | グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素 |
| JP2009500377A (ja) | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー／エス | ジシクロアルキルウレア型グルコキナーゼ活性化剤 |
| JP4960355B2 (ja) | 2005-07-14 | 2012-06-27 | ノボ・ノルデイスク・エー／エス | ウレア型グルコキナーゼ活性化剤 |
| JP5419706B2 (ja) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| JP2010515701A (ja) | 2007-01-09 | 2010-05-13 | ノボ・ノルデイスク・エー／エス | ウレアグルコキナーゼアクチベーター |
| JP5513492B2 (ja) | 2008-05-16 | 2014-06-04 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤 |
| EP2305737A4 (en) | 2008-07-22 | 2015-03-04 | Kureha Corp | PROCESS FOR PRODUCING POLYARYLENE SULFIDE HAVING REDUCED HALOGEN TERMINAL GROUP CONTENT |
| WO2010107610A1 (en) * | 2009-03-17 | 2010-09-23 | Merck Sharp & Dohme Corp. | Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds |
| AR076317A1 (es) | 2009-04-16 | 2011-06-01 | Taisho Pharmaceutical Co Ltd | Composiciones farmaceuticas que comprenden un compuesto de 1-tio-d-glucitol. |
| KR101190957B1 (ko) | 2009-08-25 | 2012-10-15 | 한올바이오파마주식회사 | 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제 |
| PT2576524T (pt) | 2010-05-26 | 2017-11-17 | Vtv Therapeutics Llc | Resumo |
| EP2392575A1 (en) * | 2010-06-04 | 2011-12-07 | LEK Pharmaceuticals d.d. | A novel synthetic approach to ß-aminobutyryl substituted compounds |
| IN2014DN09554A (enExample) | 2012-05-17 | 2015-07-17 | Transtech Pharma Llc | |
| HK1213197A1 (zh) | 2013-03-04 | 2016-06-30 | Vtv治疗有限责任公司 | 包括葡糖激酶活化劑的固體組合物及其製備和使用方法 |
| CA2903433A1 (en) | 2013-03-04 | 2014-09-12 | Vtv Therapeutics Llc | Stable glucokinase activator compositions |
-
2013
- 2013-05-15 IN IN9554DEN2014 patent/IN2014DN09554A/en unknown
- 2013-05-15 SG SG10201609644UA patent/SG10201609644UA/en unknown
- 2013-05-15 JP JP2015512779A patent/JP6234443B2/ja active Active
- 2013-05-15 EP EP13726933.8A patent/EP2849776B1/en active Active
- 2013-05-15 KR KR1020147035545A patent/KR20150013838A/ko not_active Ceased
- 2013-05-15 WO PCT/US2013/041076 patent/WO2013173417A2/en not_active Ceased
- 2013-05-15 MX MX2014013105A patent/MX360304B/es active IP Right Grant
- 2013-05-15 CN CN202410499223.0A patent/CN118453592A/zh active Pending
- 2013-05-15 CA CA2872021A patent/CA2872021C/en active Active
- 2013-05-15 EA EA201492109A patent/EA201492109A1/ru unknown
- 2013-05-15 ES ES13726933T patent/ES2878001T3/es active Active
- 2013-05-15 AU AU2013262895A patent/AU2013262895A1/en not_active Abandoned
- 2013-05-15 HK HK15103235.2A patent/HK1202458A1/xx unknown
- 2013-05-15 KR KR1020217006420A patent/KR102371364B1/ko active Active
- 2013-05-15 BR BR112014028622A patent/BR112014028622A2/pt not_active Application Discontinuation
- 2013-05-15 CN CN201380024802.XA patent/CN104349790A/zh active Pending
- 2013-05-15 SG SG11201406987UA patent/SG11201406987UA/en unknown
- 2013-11-05 US US14/071,976 patent/US10004782B2/en active Active
-
2014
- 2014-11-03 IL IL235484A patent/IL235484A0/en unknown
-
2017
- 2017-06-07 AU AU2017203835A patent/AU2017203835B2/en active Active
-
2018
- 2018-05-18 US US15/983,249 patent/US10588943B2/en active Active
-
2020
- 2020-01-16 US US16/744,956 patent/US10980861B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015517525A (ja) | 2015-06-22 |
| AU2013262895A1 (en) | 2014-11-13 |
| BR112014028622A2 (pt) | 2017-06-27 |
| US10980861B2 (en) | 2021-04-20 |
| US10588943B2 (en) | 2020-03-17 |
| KR102371364B1 (ko) | 2022-03-07 |
| JP6234443B2 (ja) | 2017-11-22 |
| HK1202458A1 (en) | 2015-10-02 |
| EP2849776A2 (en) | 2015-03-25 |
| IL235484A0 (en) | 2014-12-31 |
| EA201492109A1 (ru) | 2015-07-30 |
| US20140066372A1 (en) | 2014-03-06 |
| ES2878001T3 (es) | 2021-11-18 |
| US20180311314A1 (en) | 2018-11-01 |
| CN104349790A (zh) | 2015-02-11 |
| KR20150013838A (ko) | 2015-02-05 |
| US20200138909A1 (en) | 2020-05-07 |
| WO2013173417A2 (en) | 2013-11-21 |
| CA2872021C (en) | 2022-08-16 |
| SG11201406987UA (en) | 2014-12-30 |
| KR20210027547A (ko) | 2021-03-10 |
| CA2872021A1 (en) | 2013-11-21 |
| AU2017203835B2 (en) | 2018-11-22 |
| IN2014DN09554A (enExample) | 2015-07-17 |
| WO2013173417A3 (en) | 2014-02-20 |
| SG10201609644UA (en) | 2017-01-27 |
| CN118453592A (zh) | 2024-08-09 |
| US10004782B2 (en) | 2018-06-26 |
| AU2017203835A1 (en) | 2017-06-22 |
| MX2014013105A (es) | 2015-04-08 |
| EP2849776B1 (en) | 2021-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014013105A (es) | Composiciones de activador de glucocinasa para el tratamiento de la diabetes. | |
| BR112013029256A2 (pt) | "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina". | |
| PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
| EA201892383A1 (ru) | Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина | |
| BR112015013809A2 (pt) | derivados de exendina-4 como agonistas duplos de glp1/gip ou trigonais de glp1/gip/lucagon, seu uso e composição farmacêutica | |
| PH12015500115B1 (en) | Glucagon analogues | |
| TN2015000101A1 (en) | Exendin-4 derivatives as dual glp1/glucagon agonists | |
| MX362527B (es) | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2. | |
| MX2014015423A (es) | Analogos de peptido de exedina-4. | |
| SA519401933B1 (ar) | تركيبات صيدلية تحتوي على الأنسولين | |
| NZ603614A (en) | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator | |
| MY165122A (en) | Dipeptidyl peptidase-iv (dppiv) inhibitory peptide compound, composition containing the same, and production method for the same | |
| UA113849C2 (xx) | Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу | |
| MX2016007989A (es) | Derivados de oxindol, preparacion de los mismos y uso terapeutico en el tratamiento de enfermedades relacionadas con ampk. | |
| EA201792030A1 (ru) | Лечение пациентов с сахарным диабетом 2 типа | |
| EA201791611A1 (ru) | Лечение пациентов детского возраста с сахарным диабетом 2 типа с помощью ликсисенатида | |
| MX2020001434A (es) | Analogos de insulina acilados novedosos y usos de estos. | |
| MX366685B (es) | Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos. | |
| TW201613583A (en) | Laquinimod for the treatment of relapsing- remitting multiple sclerosis (RRMS) patients with a high disability status | |
| NZ754706A (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus | |
| MY170991A (en) | Dosing regimens of celgosivir for the treatment of dengue | |
| MX2013011561A (es) | Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| NZ724595A (en) | Glucokinase activator compositions for the treatment of diabetes | |
| WO2016126026A3 (ko) | 당뇨병 치료 조성물 및 이의 용도 | |
| PL414785A1 (pl) | Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status |
Owner name: COMCAST CABLE COMMUNICATIONS MANAGEMENT, LLC |
|
| GB | Transfer or rights |
Owner name: VTV THERAPEUTICS LLC |
|
| HC | Change of company name or juridical status |
Owner name: COMCAST CABLE COMMUNICATIONS MANAGEMENT, LLC |
|
| FG | Grant or registration |